

Optiscan Imaging Limited
Appendix 4D
Half-year report

1. Company details

Name of entity:	Optiscan Imaging Limited
ABN:	81 077 771 987
Reporting period:	For the half-year ended 31 December 2025
Previous period:	For the half-year ended 31 December 2024

2. Results for announcement to the market

Revenues from ordinary activities	down	-43%	to	\$ 339,227
Loss from ordinary activities after tax attributable to the owners of Optiscan Imaging Limited	up	-43%	to	(3,395,877)
Loss for the half-year attributable to the owners of Optiscan Imaging Limited	up	-43%	to	(3,395,877)

Dividends

There were no dividends paid or declared during the current financial period.

Comments

The loss for the consolidated entity after providing for income tax amounted to \$3,395,877 (31 December 2024: \$2,374,662).

Financial performance

During the 6-month period to 31 December 2025 (H1FY26), the consolidated entity generated ordinary revenue of \$339,227 from sales, system rentals and the provision of services, compared to \$593,757 in the previous corresponding period. The 43% decrease in sales was mainly due to lower sales of ViewnVivo[®], the company's life sciences research device. This was mainly due to significantly restricted research funding opportunities in both USA and China where the product is being marketed.

Other income generated for the half year (H1FY26) was \$1,380,209 (2025: \$2,394,516). The Company recorded research and development (R&D) incentive income for H1FY26 of \$1,155,310, a decrease of \$669,406 from the previous corresponding period (2025: \$1,824,716). Last year's R&D income was higher due to the one-off adjustment to recognise historical overseas R&D expenditure following the successful Advance and Overseas Finding, which still applies this year. There was no CRCP grant funding received this half year (H1FY26) due to delays in the gastrointestinal flexible endomicroscope project, compared to last year (H1FY25) where the Company received \$361,907.

Total expenses for H1FY26, excluding research and development and intellectual property expenses, were \$2,240,134 a decrease of \$284,450 from the corresponding period (2025: \$2,524,584). Research and development and intellectual property expenses were \$2,655,885, an increase of \$106,712 from the previous corresponding period of \$2,549,173. This higher investment in R&D has accelerated the progress of multiple applications of Optiscan's technology, and advanced clinical studies in preparation for FDA regulatory submissions.

Optiscan Imaging Limited
Appendix 4D
Half-year report

Financial position

The net assets increased by \$14,312,217 to \$22,024,231 at 31 December 2025 (30 June 2025: \$7,712,014) primarily due to the capital raised as announced on 27 August 2025, through a fully underwritten pro-rata renounceable entitlement offer. Total capital raised was \$17,751,047 with the issuance of 208,835,829 shares. The working capital position of the consolidated entity as at 31 December 2025 resulted in an excess of current assets over current liabilities of \$21,515,523 (30 June 2025: \$7,354,694).

Net cash used in operating activities was \$4,131,669, an increase of \$366,746 compared to the corresponding period (2025: operating cash outflows of \$3,764,923). Overall, there was a net increase in cash and equivalents of \$13,163,026 for the half-year (H1FY26) due to the capital raise, that will be used to undertake necessary clinical studies, testing and certification of its clinical medical devices, regulatory submissions, and progress of the flexible endomicroscope.

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	<u>2.11</u>	<u>1.93</u>

The net tangible assets per ordinary security has been calculated excluding the Right of use asset amount and Intangibles.

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

6. Dividends

Current period

There were no dividends paid or declared during the current financial period.

Previous period

There were no dividends paid or declared during the previous financial period.

7. Dividend reinvestment plans

Not applicable.

Optiscan Imaging Limited
Appendix 4D
Half-year report

8. Details of associates and joint venture entities

Not applicable.

9. Foreign entities

Details of origin of accounting standards used in compiling the report:

Not applicable.

10. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Report.

11. Attachments

Details of attachments (if any):

See the Optiscan Imaging Limited Half-Year Report for the period ended 31 December 2025 for further information.

12. Signed

Signed  _____

Date: 25 February 2026

Robert Cooke
Non-executive Chairman